This proposed rule focuses totally on PMTA evaluate treatments and material necessities, particularly with respect to software acceptance and submitting. An software might fulfill the acceptance and submitting prerequisites, but still lack vital information and facts that FDA needs to ascertain irrespective of whether it need to issue a marketing a